announces that it will be presenting to equity investors at the Whistler Capital Event conference, organized by Capital Event Management Ltd. and being hosted at the Fairmont Chateau Whistler, in Whistler, British Columbia, February 21 to 23, 2025.

reports results for its first quarter of fiscal 2025 ended December 31, 2024 (“Q1”).

announces that it expects to file the financial statements and management disclosure and analysis for its first quarter of fiscal 2025 ended December 31, 2024 (“Q1 2025”) prior to the start of trading on February 13, 2025

announces that it has received C$ 2.4 million in new equity capital from the partial exercise of expiring share purchase warrants.

announces its intentions to broaden its platform capabilities to enable production of a wider range of test ingredients (“Antigens”) by using recombinant production technologies.

announces its intentions to broaden its platform capabilities to enable production of a wider range of test ingredients (“Antigens”) by using recombinant production technologies.

reports results for its fiscal year and fourth quarter ended September 30, 2024 (“2024” and “Q4”) with record revenues, reflective of ongoing progress to increase sales from its diagnostic-test related ingredients and devices businesses and that resulted in material net income for 2024 and Q4.

announces that it expects to file the financial statements and management disclosure and analysis for its fourth quarter of fiscal 2024 ended September 30, 2024 (“Q4 2024”) prior to the start of trading on December 19, 2024. At 11:00 AM ET on that day, Microbix intends to hold a webinar discussion of Q4 2024 results with its CEO, CFO, and COO.

with EMQN announce the go-live of a program to support the accurate identification of patients who carry a gene-variant associated with increased susceptibility to hearing loss following treatment with a widely-used class of antibiotics.

announces the initiation of a Normal Course Issuer Bid (“NCIB”) program for the repurchase and cancellation of outstanding common shares.